pamorelin is a synthetic pentapeptide selective ghrelin / growth hormone secretagogue receptor (GHS-R1a) agonist, originally developed by Novo Nordisk in the late 1990s as a research compound. The peptide consists of five amino acids with two non-natural residues (Aib at position 1, D-2-naphthylalanine at position 3) designed to enhance receptor selectivity and metabolic stability. Ipamorelin is studied as one of the most selective GHS-R1a agonists characterized in research literature, reportedly stimulating endogenous growth hormone release without significant effects on cortisol, prolactin, ACTH, or aldosterone secretion — a selectivity profile that distinguishes it from earlier-generation GH secretagogues such as GHRP-6 and hexarelin. The compound is investigated in preclinical research for somatotropic axis pharmacology, GH release dynamics, and receptor selectivity studies, and is frequently paired with GHRH analogs (CJC-1295 No DAC, tesamorelin, sermorelin) in combined-pathway research protocols.

Benefits (Research Focus)

• Selective GHS-R1a agonism — studied as a highly selective ghrelin receptor agonist with minimal off-target receptor activity

• GH release research — investigated for endogenous growth hormone release from pituitary somatotropes

• Hormone selectivity — explored for reported minimal effects on cortisol, prolactin, ACTH, and aldosterone vs. other GH secretagogues

• IGF-1 axis signaling — examined for downstream hepatic IGF-1 production and somatotropic endpoints

• Combination pharmacology — researched alongside GHRH analogs (CJC-1295, tesamorelin) for paired pathway studies

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.